Periprocedural myocardial injury during elective percutaneous coronary intervention: is it important and how can it be prevented?. Issue 10 (6th May 2010)

• Record Type: Journal Article
• Authors: Cuculi, F; Lim, C C S; Banning, A P
• Is Part Of: Heart. Volume 96:Issue 10(2010)
• Page Start: 736
• Page End: 740
• Publication Date: 2010-05-06
• Subjects: PTCA–troponin–statins -- HMG CoA–clopidogrel–platelet aggregation inhibitors -- coronary angioplasty -- coronary stenting -- microvascular -- preconditioning -- anticoagulation; Heart -- Diseases -- Treatment -- Periodicals; Cardiology -- Periodicals; 616.12
• DOI: 10.1136/hrt.2009.186189
• Languages: English
• ISSNs: 1355-6037

Abstract

Abstract : Periprocedural myocardial injury (PMI) is common after percutaneous coronary intervention (PCI). Periprocedural infarction (myocardial infarction type 4a) occurs after at least 10% of PCI procedures and has an impact on long-term prognosis. Measurement of biomarkers to allow assessment of PMI is an important tool for clinical and research purposes and should be routine after every PCI (troponin I or T and CK-MB). The importance of oral and intravenous antiplatelet agents and other drugs which have been proven to reduce PMI is discussed.